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ABSTRACT. Silver nanoparticles (Ag-NPs) can attach to flexible polymeric chains of antibiotics, hence it can be 
used in combination with antibiotics against resistant bacteria. In this study, minimum inhibitory concentration (MIC), 
minimum bactericidal concentration (MBC), and MBC/MIC ratio of Ag-NPs and antibiotics (gentamicin, tetracycline, 
erythromycin, ciprofloxacin, nalidixic acid, cefixime, cephalexin, amoxicillin, ampicillin, and penicillin) were quanti-
fied against 50 Escherichia coli isolates (25 human urinary tract infection and 25 avian colibacillosis). All isolates had 
been assigned as four phylogenetic groups A, B1, B2, and D. The results showed that the majority of the human and 
broiler isolates belonged to phylogenetic groups A and B2. MBC/MIC ratio of Ag-NPs in combination with antibiotics 
was assessed. It was found that the MIC of the majority of broiler isolates to Ag-NPs was equal to or greater than 50 
µg/ml. To conclude, a combination of penicillin and ciprofloxacin with Ag-NPs exhibited profound impact against 
isolates, the combinations might be applicable for treating multidrug-resistant bacteria.
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INTRODUCTION
Extra-intestinal pathogenic Escherichia coli (Ex-PEC) causes a variety of diseases outside the 
intestine, including urinary tract infections (UTIs) 
(Skjot-Rasmussen, et al. 2012), meningitis, sepsis, 
abdominal infections, osteomyelitis, cellulitis, and 
colibacillosis in poultry (Johnson, et al. 2007). E. coli 
has been characterized in four major phylogenetic 
groups including A, B1, B2, and D. Most commensal 
E. coli strains belong to phylogenetic groups A and B1 
whereas the most virulent strains belong to groups B2 
and D (Hussain, et al. 2012; Kazemnia, et al. 2014). 
Generally, human uropathogenic E. coli (UPEC) 
might be transferred from food chains (Singer 2015). 
A study indicates that retail meat contaminated with 
ExPEC strains, were associated with the antimicro-
bial-resistant E. coli causing urinary UTIs (Walk, et 
al. 2007). The application of antibiotics in the poultry 
industry is a risk factor for the emergence of antimi-
crobial resistant bacteria (Furtula, et al. 2010). Since 
multidrug resistant (MDR) bacteria is increasing, 
then, it requires to be considered as a major public 
health threat. The increase of MDR bacteria has led 
to find and develop a novel generation of safe anti-
microbials to control those microorganisms. Because 
of their antimicrobial properties (Kim, et al. 2007), 
inorganic nanomaterials such as silver nanoparticles 
(Ag-NPs) are widely used in medical and consumer 
products, including antiseptic agents, medical devic-
es, water purification systems, food packaging, and 
health care products (Park, et al. 2010). Mechanisms 
by which Ag-NPs exert their antibacterial effects to 
overcome bacteria are as follows: penetrating to bac-
terial cell which alters transportation of electrolytes 
and metabolites (Ansari, et al. 2014), and affects 
membrane-bound enzymes leading to disruption of 
ATP production; destroying the stability of LPS lead-
ing to an increase in the permeability of outer mem-
brane; damaging vital enzymes, proteins, and DNA as 
a result of binding of Ag-NPs with them (Yang, et al. 
2012; You, et al. 2012), owing to the fact that Ag-NPs 
have a great affinity to react with sulfur- or phospho-
rus-containing compounds (Silambarasan and Jayan-
thi 2013; Tamboli, et al. 2012); and generating reac-
tive oxygen species which leads to death of bacteria 
(Xu, et al. 2012; You, et al. 2012). It has been reported 
that combination of antibiotics and Ag-NPs may act 
as an antibiotic carrier, facilitating the approaching of 
hydrophilic antibiotics to bacterial surface (Ghosh, et 
al. 2012), and then nano-silver drug carriers may help 
them to cross into bacteria, causing more damage to 
the cell. Additionally, Ag-NPs may share their mech-
anism of actions with antibiotics to cope with resis-
tant bacteria. Moreover, regarding different modes of 
actions of antibiotics and Ag-NPs, it can be expected 
if a bacterium exhibits resistance to one agent, the 
other agent may overcome the bacterium with differ-
ent mechanisms of action. Ag-NPs have a very lower 
natural tendency to induce microbial resistance than 
do antibiotics (Chudasama, et al. 2010). The aim of 
the present study was to investigate the effects of the 
simultaneous application of Ag-NPs and commonly 




A total of 50 E. coli strains (25 from UTIs and 
25 from broiler colibacillosis) were included in this 
study. All strains (tables 1 and 2) had previously been 
classified using triplex PCR as proposed by Clermont 
et al. (Clermont, et al. 2000) in our previous work 
(Kazemnia, et al. 2014). The results of phylogenetic 
typing of strains are in tables 1 and 2. 
Susceptibility of E. coli isolates to Ag-NPs
Commercially manufactured 20 nm Ag-NPs (US 
Research Nanomaterials, Inc., Houston, USA) was 
used to treat the isolates. Firstly, all E. coli isolates 
were grown overnight and washed twice, then cells 
were re-suspended in Muller-Hinton broth until their 
concentration reached 108 CFU/mL. The concen-
tration was evaluated by optical density at 600 nm 
(OD600~ 0.1-0.13). Microdilution method was em-
ployed to examine the susceptibility of isolates to 
different concentrations of Ag-NPs. An amount of 
100 µL of each overnight culture and 800 µL of fresh 
Mueller-Hinton broth were added to each well in a 
48-well microplate. To treat each strain with a final 
concentration of Ag-NPs (2.5, 5, 10, 20, 30, 40, 50, 
100 µg/mL), 100 µL of stock solutions of prepared 
Ag-NPs (25, 50, 100, 200, 300, 400, 500, 1000 µg/
mL) was added to each well. The microplates were 
then incubated at 37 °C for 24 h. The MIC was de-
termined by measuring the optical density of cultured 
bacteria using a spectrophotometer at 600 nm. (CLSI 
2012). Five microliters of each well was plated on 
Luria–Bertani agar and incubated further at 37 °C in 
order to determine the minimum bactericidal concen-
tration (MBC) (Ayala-Núñez, et al. 2009).
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Table 1. MIC, MBC and MBC/MIC ratio of SNP and antibiotics alone and in combination against different urinary phylotypes of 
E.coli.






































1 A 25 25 25 25 1 75 100 ** 25 50 1 25 50 1 100 * 1.5
2 B2 25 25 * * ** * * ** * * ** * * ** * * 1
3 A 50 75 * * ** * * ** * * ** * * ** 100 * 1
4 D 50 50 25 25 1 75 100 ** 50 75 1 50 100 ** 75 100 25
5 D 75 100 50 50 1 * * ** * * ** * * ** * * 1
6 B2 100 100 25 25 1 * * ** * * ** * * ** 25 100 25
7 B2 50 50 25 25 1 * * ** * * ** * * ** * * **
8 D 50 75 * * 1 * * ** * * ** * * ** * * **
9 D 75 100 50 50 1 * * ** * * ** * * ** * * **
10 A 25 25 25 25 1 * * ** 25 50 1 * * 1 25 * 75
11 D 75 75 100 * 1 * * ** 50 100 1 * * 1 * * **
12 A 50 50 25 25 1 100 * ** 25 75 3 25 50 1 25 * 75
13 B2 100 100 * * 2 * * ** * * ** * * ** * * 1.33
14 A 25 25 75 * 2 * * ** * * ** * * ** * * 1
15 D 100 100 25 25 1 * * ** * * ** * * ** * * **
16 A 100 100 * * 1 * * ** * * ** * * ** 25 * 75
17 B2 * * * * ** * * ** * * ** * * ** * * **
18 B2 75 75 50 50 1 * * ** * * ** * * ** * * 1
19 B2 75 75 25 25 1 100 * ** 50 75 1 25 50 1 50 * 75
20 B2 75 100 75 75 1 100 * ** 25 100 1 25 100 1 25 * 75
21 B2 100 100 50 50 1 100 * ** 50 100 1 25 100 1 25 * 75
22 B2 100 100 50 50 1 * * ** * * ** * * ** * * **
23 D 75 75 50 50 1 * * ** * * ** * * ** * * 1.33
24 A 100 100 50 50 1 100 * ** 25 100 1 25 50 1 25 * 75
25 A 75 100 50 50 3 100 * ** 25 100 1 25 50 1 25 100 75
Table 1 (continued)






































1 A 25 25 12.5 25 6 * * 1.33 100 * 1 25 50 1 * * **
2 B2 25 25 12.5 25 1 * * ** * * ** 100 * 2 * * **
3 A 50 75 * * ** * * ** * * ** * * ** * * **
4 D 50 50 6 50 1 * * 8.33 50 100 8.33 25 50 25 50 * **
5 D 75 100 12.5 50 1 * * ** * * 4.17 * * ** * * **
6 B2 100 100 25 * 1 50 75 2 * * ** 50 50 8.33 * * **
7 B2 50 50 75 100 25 * * ** * * ** 50 50 2 * * **
8 D 50 75 * * ** * * ** * * ** * * ** * * **
9 D 75 100 * * 1 * * ** * * ** 50 75 4.1 * * **
10 A 25 25 100 * 1 25 50 8.3 50 100 4.17 25 50 3 75 * **
11 D 75 75 * * ** * * ** * * ** 50 50 8.33 * * **
12 A 50 50 100 * 1 * * 8.3 * * 2 25 50 1 75 * **
13 B2 100 100 * * ** * * ** * * ** * * ** * * **
14 A 25 25 * * ** * * ** * * ** * * ** * * **
15 D 100 100 12.5 * 25 75 100 4.17 * * ** * * ** * * **
16 A 100 100 * * ** * * ** * * ** * * ** * * **
17 B2 * * * * ** * * ** * * ** * * ** * * **
18 B2 75 75 * * ** * * ** * * ** * * ** * * **
19 B2 75 75 25 50 1 50 75 25 50 100 ** 25 50 1 * * **
20 B2 75 100 12.5 25 1 50 75 25 50 100 ** 50 50 6 * * **
21 B2 100 100 12.5 25 1 50 75 25 50 100 ** 25 50 12 100 * **
22 B2 100 100 * * ** * * ** * * ** * * ** * * **
23 D 75 75 25 75 1 * * 8.33 50 100 ** 25 25 2 * * **
24 A 100 100 6 25 1 50 75 25 50 100 1 12.5 75 2 * * **
25 A 75 100 6 25 1 50 100 25 100 * ** 25 75 2 * * **
* refers to >100; ** refers to not determined; SNP refers to Ag-NPs.
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Table 2. MIC, MBC and MBC/MIC ratio of SNP and antibiotics alone and in combination against different colibacillosis phylotypes 
of E.coli.






































1 B2 50 75 25 50 3 * * ** 25 100 4.1 50 100 4.1 25 50 6
2 B2 100 100 25 50 1 * * ** 25 100 12 50 100 4.1 25 75 12
3 A 50 75 25 50 3 * * ** 50 100 25 50 * 4.1 25 * 8.3
4 B1 50 50 50 75 12 * * ** * * ** * * ** * * **
5 A 1 25 25 25 1 * * ** 25 100 12 50 100 4.1 25 75 4
6 B1 75 75 25 50 6 * * ** * * ** * * ** * * **
7 D 50 100 12 25 3 * * ** 50 * 12.5 75 * 4.1 25 50 12
8 B1 25 25 25 25 1 * * ** * * ** 75 * 2.1 * * **
9 B2 75 75 25 50 1 * * ** 50 * 8.3 50 * 4.1 25 100 8.3
10 B2 50 50 12 25 1 * * ** 50 * 8.3 50 100 2.1 100 * 4
11 B2 75 75 25 50 3 * * ** 75 * 8.3 100 * 4.1 25 50 6
12 A 50 50 25 25 1 * * ** * * ** * * ** * * **
13 A 3 25 12 25 1 100 * ** 50 * 8.3 50 100 4.1 * * 4
14 B2 1 25 12 25 1 100 * 2 75 * 8.3 100 * 4.1 25 75 12
15 A 50 100 25 50 3 * * ** 75 * 8.3 * * 4.1 * * **
16 A 50 50 25 50 3 * * ** * * 8.3 75 100 4.1 * * **
17 A 50 50 12 25 1 * * ** 50 * 4.1 * * 4.1 * * **
18 D 50 50 25 50 3 * * ** 50 * 8.3 25 100 4 * * **
19 D 50 50 12 25 1 * * ** 50 100 8.3 100 * 4.1 * * 2
20 D 50 50 12 25 3 * * ** 75 * 8.3 * * 4.1 * * **
21 B2 50 75 12 25 3 * * ** * * 4.1 75 * 2.1 25 100 8.3
22 B1 25 25 25 50 3 * * ** 100 * 6.25 * * 3 * * **
23 A 25 25 12 25 3 * * ** * * 8.3 75 * 2.1 * * **
24 A 12 25 12 25 1 * * ** 75 * 8.3 75 100 4.1 25 50 6
25 D 50 75 25 50 2 * * ** 75 100 8.3 100 * ** * * **
Table 2 (continued)






































1 B2 50 75 75 * 100 * * ** 50 * 8.33 100 * 2 * * **
2 B2 100 100 50 * 100 * * ** 100 * 8.33 25 100 16.7 50 100 3
3 A 50 75 * * ** * * ** * * ** 25 100 12.5 * * **
4 B1 50 50 * * 4 * * ** 100 * 8.33 * * ** * * **
5 A 1 25 50 70 3 100 * 33.3 50 100 25 25 50 25 25 100 12.5
6 B1 75 75 100 * 8.3 * * ** 100 * 4 100 * ** * * **
7 D 50 100 50 * 50 * * ** 100 * 8.3 25 50 25 75 * 4
8 B1 25 25 50 * 16.7 * * ** 100 * 4 * * ** * * **
9 B2 75 75 50 * 75 * * ** * * 2 75 * 8.3 50 100 2
10 B2 50 50 50 * 75 * * ** 100 * ** 100 * 8.3 * * **
11 B2 75 75 75 * 75 * * ** 100 * ** 50 * 12.5 75 * 2
12 A 50 50 50 * 75 * * ** 100 * 6.25 * * ** * * **
13 A 3 25 * * 6.25 * * ** * * ** 25 50 12 75 * **
14 B2 1 25 75 * 50 75 * ** 100 * ** 25 50 6 25 * 6.25
15 A 50 100 50 * 6.25 * * ** * * ** 25 50 6 50 * **
16 A 50 50 75 * 16.7 * * ** * * ** 25 50 4 50 * 4
17 A 50 50 50 * 16.7 * * ** * * ** 25 50 12 50 * 3
18 D 50 50 50 * 75 * * ** * * ** 50 100 16.7 50 * 4
19 D 50 50 100 * 75 * * ** * * ** 25 100 8.3 50 * 3
20 D 50 50 50 * 100 * * ** * * ** 50 100 16.7 50 * **
21 B2 50 75 50 * 33.3 * * ** 100 * ** 12 100 25 25 * **
22 B1 25 25 25 50 12 100 * ** 100 * ** 50 * 12.5 50 * **
23 A 25 25 50 * 33.3 * * ** 100 * ** 25 50 12 75 * **
24 A 12 25 50 75 8.3 * * ** * * ** 25 75 25 * * **
25 D 50 75 * * ** * * ** * * ** * * ** * * **
* refers to >100; ** refers to not determined; SNP refers to Ag-NPs.
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Susceptibility of E. coli isolates to antibiotics
E. coli strains were tested for antimicrobial sus-
ceptibility using the same procedure described for 
susceptibility testing of isolates for Ag-NPs. The an-
tibiotics used in this essay belonging to six different 
classes of antibiotics: aminoglycosides (gentamicin); 
tetracyclines (tetracycline); macrolides (erythromy-
cin); quinolones (ciprofloxacin and nalidixic acid); 
cephalosporins (cefixime and cephalexin); penicillins 
(amoxicillin, ampicillin, and penicillin) (Sigma-Al-
drich, St. Louis, MO, USA). Stock solutions of each 
antibiotic were prepared with concentrations of 15.6, 
31.25, 62.5, 125, 250, 500, 750, 1000 mg/mL. Each 
strain was then treated with a final concentration of 
1.56, 3.125, 6.25, 12.5, 25, 50, 75, 100 mg/mL of each 
antibiotic in a 48-well microplate.
Susceptibility of E. coli isolates to Ag-NPs in 
combination with antibiotics
For determination of MIC and MBC of each iso-
late, the sub-inhibitory concentration of 5 µg/mL of 
Ag-NPs in combination with each of antibiotics was 
separately applied to each of the strains to examine 
MIC and MBC of combined agents. The interaction 
of antibiotics and Ag-NPs were evaluated using 5 µg/
mL of Ag-NPs and 1.56, 3.125, 6.25, 12.5, 25, 50, 
75, 100 mg/mL of each antibiotic to determine MIC 
and MBC. The procedure was performed as described 
previously (CLSI 2012).
Statistical analysis
All experiments were carried out at least in three 
replicates and obtained data were analyzed in the 
SPSS (Version 21, SPSS Inc., Chicago, IL).
RESULTS
MIC and MBC
The MIC and MBC patterns of 50 strains to 10 
antibacterial agents and Ag-NPs are shown in tables 1 
and 2. According to the MIC and MBC results, coli-
bacillosis isolates exhibited the highest rates of resis-
tance to penicillin and the lowest resistance to gen-
tamycin. It was found that the MIC of the majority 
of isolates from broilers to Ag-NPs was equal to or 
greater than 50 µg/ml. Multi-drug resistance of E. coli 
isolates from human was higher than E. coil isolates 
from broilers. Statistical analysis demonstrated that, 
among colibacillosis isolates, bactericidal effect of 
5 µg/ml in combination with penicillin, gentamycin, 
cephalexin, amoxicillin, erythromycin, tetracycline, 
cefixime, ciprofloxacin, nalidixic acid, and ampicillin 
was 100, 92, 80, 33.3, 33.3, 30.8, 10, 8.7, 0 and 0, 
respectively. The effect of simultaneous application 
of Ag-NPs and antibiotics in 34.8% of colibacillosis 
strains was bactericidal and in 65.2% was bacteriostat-
ic. Maximum bactericidal effects of combined agents 
on the broiler strains belonged to genotypes B1, D, B2 
and A calculated as 46.7, 35.7, 34 and 31.4 % respec-
tively. The bactericidal effect of combination of 5µg/
ml of Ag-NPs with each of antibiotics (ciprofloxacin, 
cefixime, erythromycin, tetracycline, gentamycin, na-
lidixic acid, ampicillin, and amoxicillin) in the case 
of human strains were 81.3, 60, 50, 44.8, 22, 16.7, 10, 
and 9%, respectively. The effect of the combination of 
5 µg/ml of Ag-NPs with antibiotics in70.4% of strains 
from human was bactericidal, and in 29.6% of strains 
was bacteriostatic in total. The maximum bactericidal 
effect of combined agents against human strains be-
longed to genotypes of A, B2, and D calculated as 75, 
70, and 63% respectively.
DISCUSSION
There is a need for a new generation of antibiot-
ics to overcome drug-resistant bacteria because of the 
rapid development of antimicrobial resistance (Ansa-
ri, et al. 2013). According to previous studies, there 
is some evidence proving that Ag-NPs have potent 
antimicrobial effects individually (Ansari, et al. 2014; 
Radzig, et al. 2013) and show synergistic activity in 
combination with antibiotics (Dhas, et al. 2013; La-
vanya, et al. 2013). As stated in some works, whether 
an agent by itself or in combination with the other 
agents is considered bacteriostatic when this ratio is 
equal to or greater than 16, and if this ratio is less than 
or equal to 4, the agent represents bactericidal manner 
(Das, et al. 2016; Prema, et al. 2017). In this study, an 
antibacterial performances using microdilution meth-
od against isolates elucidated that combination of a 
penicillin (in colibacillosis strains) and ciprofloxacin 
(in UTI strains) with Ag-NPs exhibited profound im-
pact and could be used for coping with multidrug-re-
sistant E. coli. According to the results, most of the 
combined agents used in this study had bactericidal 
effects. Gentamicin plus 5µg/ml offered itself to be 
a promising bactericidal compound against MDR E. 
coli. The results obtained from this study are consis-
tent with that of other researches. Indeed, gentamy-
cin plus Ag-NPs in several studies demonstrated en-
hanced or even synergistic antibacterial effect against 
Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus pneumoniae, Streptococcus pyogenes, 
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/08/2021 03:14:00 |
J HELLENIC VET MED SOC 2019, 70(3)
ΠΕΚΕ 2019, 70(3)
1652 A. KAZEMNIA, M. AHMADI, K. MARDANI, M. MORADI, R. DARVISHZADEH
Streptococcus agalactiae, Streptococcus mutans, 
Bacillus cereus, Bacillus subtilis, Escherichia coli, 
Escherichia fergusonii, Shigella flexneri, Klebsiella 
pneumoniae, Salmonella typhi, Enterococcus faeca-
lis, Aeromonas hydrophila, Vibrio parahaemolyticus, 
Edwardsiella tarda and Pseudomonas aeruginosa 
(Barapatre, et al. 2016; Chhibber, et al. 2017; Ebra-
himi, et al. 2017; Jamaran and Zarif 2016; Katva, et 
al. 2017; Mohamed, et al. 2017; Panacek, et al. 2015; 
Satapathy, et al. 2017; Verma, et al. 2017; Wang, et 
al. 2016).Moreover, in a good agreement with re-
ported data in the literature, penicillin (Ebrahimi, et 
al. 2017; Panacek, et al. 2015) in contrary to some 
studies (Deng, et al. 2016; Natan and Banin 2017; 
Wang, et al. 2016) and ciprofloxacin in the case of 
human strains (Mohamed, et al. 2017; Yallappa, et al. 
2015) in accord with our data (Panacek, et al. 2015) 
showed significant increase in antibacterial activities 
when conjugated with Ag-NPs. Furthermore, tetracy-
cline (Deng, et al. 2016; Ebrahimi, et al. 2017; Natan 
and Banin 2017), amoxicillin (Mohamed, et al. 2017), 
cephalosporin (Refat, et al. 2017), erythromycin (Yal-
lappa, et al. 2015) showed partially increase in anti-
bacterial activities in the presence of Ag-NPs. On the 
other hand, to the contrary to our study, ampicillin 
(Satapathy, et al. 2017), nalidixic acid (Tawfeeq, et 
al. 2017) have been mentioned to have a synergistic 
effect. This might be attributed to the joint mechanism 
of action between antibiotic and Ag-NPs (Wang, et al. 
2016). Combination may trigger an enhanced mem-
brane permeability and/or reactive oxygen species 
production. However, little is known about the inter-
action between Ag-NPs and antibiotic, and also the 
presence of resistant genes to Ag-NPs. The difference 
in the behavior of the combination of Ag-NPs with 
antibiotics discussed in the literature could be due to 
the presence of resistance genes to Ag+, applied doses, 
the size, and shape of Ag-NPs, and the mechanisms of 
resistance to Ag-NPs in bacteria. The antibacterial ca-
pacity of Ag-NPs is dependent on the size, dose, and 
the shape of Ag-NPs (Majeed, et al. 2016; Prema, et 
al. 2017; Zheng, et al. 2018). The Ag-NPs in small size 
reveal higher antibacterial performance (Zheng, et al. 
2018). The mechanisms by which bacterial cells exert 
resistance to Ag+ are as follows: utilizing Ag+ ATPase 
efflux pumps; multiple antibiotic resistance genes; 
ybdE, ylcD, ylcC, ylcB, ylcA, ybcZ genes (Nagy, et al. 
2011; Silver, et al. 2006); some periplasmic Ag+ bind-
ing proteins (Muhling, et al. 2009; Silver, et al. 2006); 
plasmids carrying metal resistance genes (Silver, et al. 
2006). However, bacterial resistance to Ag-NPs has 
not been proven yet. 
The MBC/MIC ratio has been used to consid-
er whether an agent is a bactericide or bacteriostat-
ic. Conversely, there were significant differences in 
bacteriostatic and bactericidal manners of combined 
agents among the phylotypes of human and broiler 
strains. The administration of 5µ/mL of Ag-NPs com-
bined with antibiotics against the phylotypes A, B2, 
and D in the case of human strains exerted bacteri-
cidal action, whereas in the case of broiler strains it 
was bacteriostatic manner. The authors speculate that 
this effect is probably due to the tolerance (Das, et al. 
2016) of broiler strains against Ag+ and/or Ag-NPs. 
Since these differences among phylotypes of E. coli 
have not been studied yet, further studies are required.
CONCLUSION
The results of this study suggest that Ag-NPs com-
bined with antibiotics exhibit excellent bactericidal 
effect towards drug resistant E. coli. Nevertheless, 
one of the profound concerns despite the benefits of 
Ag-NPs is now the toxicity of Ag-NPs on mamma-
lian cells, which needs to be investigated further. To 
the best of our knowledge, it is the first report that of 
MBC/MIC ratio of simultaneous application of com-
mercially prescribed antibiotic and Ag-NPs against 
clinical strains. 
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